Nuclear magnetic resonance (NMR) is considered one of the “big guns” of the analytical instrument industry, with annual sales rapidly approaching the $1 billion mark. While one may be impressed by the sheer size of NMR systems with high-strength magnets, the probe, which provides the means to interface the sample with the instrument, is an […]
The metabolome is the full set of metabolites—the chemical fingerprints left behind by cellular processes—in an organism. The pharmaceutical industry is particularly interested in the potential of metabolomics research, because metabolites can serve as biomarkers for disease states and drug efficacy, and they can reveal toxicity during the drug discovery process. Metabolomics offers instrument manufacturers […]
In April, Oxford Instruments announced that it is in negotiations “to exit the High Field NMR business.” The divestment is expected to lead to a one-time noncash write off not to exceed £3 million ($5.9 million).
Protasis introduced the Discovery High Throughput Structure Confirmation NMR Workstation, an automated MicroFlow NMR system for medicinal chemists, for use with Bruker or Varian NMRs and third-party confirmation and data archiving software. It features the Protasis/MRM CapNMR probe, Protasis One-Minute NMR software, the CTC/Leap PAL liquid handler, high-pressure pumps and web-based software for control. JEOL […]
Pay Invoice
Latest Blogs
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
